Evidence map›Paper›PMID 27706215›Full record

ArticlePloS one2016

Alterations of Myelin Content in Parkinson's Disease: A Cross-Sectional Neuroimaging Study.

Douglas C Dean, Jitka Sojkova, Samuel Hurley, Steven Kecskemeti, Ozioma Okonkwo, Barbara B Bendlin, Frances Theisen, Sterling C Johnson, Andrew L Alexander, Catherine L Gallagher

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Review of in vitro approaches for assessing the toxicity of chemical stressors across diverse physiological systems.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Douglas C DeanWaisman Center, University of Wisconsin Madison, Madison, Wisconsin, United States of America.ORCID http://orcid.org/0000-0002-7057-1285
Jitka SojkovaWilliam S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States of America.
Samuel HurleyOxford Centre for Functional Magnetic Resonance Imaging of the Brain, University of Oxford, Oxford, Oxfordshire, United Kingdom.
Steven KecskemetiWaisman Center, University of Wisconsin Madison, Madison, Wisconsin, United States of America.
Ozioma OkonkwoWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Barbara B BendlinWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States of America.
Frances TheisenWilliam S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States of America.
Sterling C JohnsonWilliam S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States of America.
Andrew L AlexanderWaisman Center, University of Wisconsin Madison, Madison, Wisconsin, United States of America.
Catherine L GallagherWilliam S. Middleton Memorial Veterans Hospital, Madison, Wisconsin, United States of America.
University of Wisconsin–Madison · USUniversity of Oxford · GB

Funding

Wisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6M
WISCONSIN CENTER ON MENTAL RETARDATION: CORE SUPPORTP30HD003352 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI MAILICK, MARSHA RUTH · 1985 to 2015
$25.2M
Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CHAPPELL, RICHARD J · 2009 to 2018
$16.2M
POSTDOCTORAL TRAINING IN MENTAL RETARDATION RESEARCHT32HD007489 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI Sigan L Hartley · 1995 to 2026
$6.0M
White matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR01AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2012 to 2023
$5.3M
White matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR56AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2017 to 2017
$759k
Technologies for Improved Quantitative Relaxometry in Awake ChildrenR21HD078119 · NICHD · UNIVERSITY OF WISCONSIN-MADISON · PI ALEXANDER, ANDREW L · 2014 to 2015
$401k
Longitudinal MRI in Preclinical Parkinson DiseaseI01CX000555 · VA · WM S. MIDDLETON MEMORIAL VETERANS HOSP · PI GALLAGHER, CATHERINE L. · 2012 to 2023
–
CSRD VA I01 CX000555NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG037639NIA NIH HHS R56 AG037639NICHD NIH HHS P30 HD003352NICHD NIH HHS R21 HD078119NICHD NIH HHS T32 HD007489
6 · The paper itself

Abstract

Alterations to myelin may be a core pathological feature of neurodegenerative diseases. Although white matter microstructural differences have been described in Parkinson's disease (PD), it is unknown whether such differences include alterations of the brain's myelin content. Thus, the objective of the current study is to measure and compare brain myelin content between PD patients and age-matched controls. In this cross-sectional study, 63 participants from the Longitudinal MRI in Parkinson's Disease study underwent brain MRI, Unified Parkinson's Disease Rating Scale (UPDRS) scoring, and cognitive asessments. Subjects were imaged with the mcDEPSOT (multi-component driven equilibrium single pulse observation of T1 and T2), a multicomponent relaxometry technique that quantifies longitudinal and transverse relaxation rates (R1 and R2, respectively) and the myelin water fraction (VFM), a surrogate for myelin content. A voxel-wise approach was used to compare R1, R2, and VFM measures between PD and control groups, and to evaluate relationships with age as well as disease duration, UPDRS scores, and daily levodopa equivalent dose. PD subjects had higher VFM than controls in frontal and temporal white matter and bilateral thalamus. Greater age was strongly associated with lower VFM in both groups, while an age-by-group interaction suggested a slower rate of VFM decline in the left putamen with aging in PD. Within the PD group, measures of disease severity, including UPDRS, daily levodopa equivalent dose, and disease duration, were observed to be related with myelin content in diffuse brain regions. The age-by-group interaction suggests that either PD or dopaminergic therapies allay observed age-related myelin changes. The relationships between VFM and disease severity measures suggests that VFM may provide a surrogate marker for microstructural changes related to Parkinson's disease.

Indexed as

AgedAntiparkinson AgentsBrainCross-Sectional StudiesFemaleHumansLevodopaMagnetic Resonance ImagingMaleMiddle AgedMyelin SheathNeuroimagingParkinson DiseaseAntiparkinson AgentsLevodopa

Identifiers

PMID27706215
PMCPMC5051727
OpenAlexW2549276155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.